West, R;
Eden Evins, A;
Benowitz, NL;
Russ, C;
McRae, T;
Lawrence, D;
Aubin, LS;
... Anthenelli, RM; + view all
(2018)
Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES.
Addiction
, 113
(8)
pp. 1507-1516.
10.1111/add.14208.
Preview |
Text
West_et_al-2017-Addiction.pdf - Published Version Download (251kB) | Preview |
Abstract
AIMS: To assess 1) how far efficacy of front line smoking cessation pharmacotherapies vary as a function of smoker characteristics, and 2) associations between these characteristics and success of smoking cessation attempts. DESIGN: Prospective correlational study in the context of a double blind randomised trial. The outcome was regressed individually onto each covariate after adjusting for treatment, and then a forward stepwise model constructed. Treatment moderator effects of covariates were tested by treatment-by-covariate interactions. SETTING: Health service facilities in multiple countries. PARTICIPANTS: Data came from 8120 smokers willing to make a quit attempt, randomized to varenicline, bupropion, nicotine replacement therapy (NRT) or placebo in Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) between November 30, 2011 and January 13, 2015. MEASUREMENTS: Smoker characteristics measured at baseline were country, psychiatric history, sex, age, body mass index (BMI), ethnic group, lifetime suicidal ideation/behaviour, anxiety, depression, aggression, psychotropic medication, history of alcohol/substance use disorder, age of starting smoking, cigarette dependence (Fagerström Test for Cigarette Dependence [FTCD]) and prior use of study medicines. Outcome was biochemically confirmed continuous abstinence weeks 9-24 from start of treatment. FINDINGS: No statistically significant treatment-by-covariate interactions were found. Odds of success were independently positively associated with age (odds ratio [OR] = 1.01; 95% CI = 1.00, 1.01), BMI (1.01; 1.00, 1.02) and age of starting smoking (1.03; 1.02, 1.04). Odds were independently negatively associated with US (versus non-US) study site (0.53; 0.46, 0.61), black (versus white) ethnic group (0.57; 0.45, 0.72), mood disorder (0.85; 0.73, 0.99), anxiety disorder (0.71; 0.55, 0.90) and psychotic disorder (0.73; 0.50, 1.07), taking psychotropic medication (0.81; 0.68, 0.95), FTCD (0.89; 0.87, 0.92) and previous use of NRT (0.78; 0.67, 0.91). CONCLUSIONS: While a range of smoker characteristics-including psychiatric history, cigarette dependence and prior use of nicotine replacement therapy (NRT)-are associated with lower cessation rates, they do not substantially influence the efficacy of varenicline, bupropion or NRT.
| Type: | Article |
|---|---|
| Title: | Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/add.14208 |
| Publisher version: | http://dx.doi.org/10.1111/add.14208 |
| Language: | English |
| Additional information: | © 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | Treatment effects, smoking cessation, varenicline |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Behavioural Science and Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10045507 |
Archive Staff Only
 |
View Item |
